Medidata is providing the underlying technology, while Icon is contributing its pre-validated surveys.
The U.S. National Cancer Institute is working with Dell, Terascala and the Translational Genomics Research Institute to bolster its pediatric oncology research capabilities. The NCI ultimately hopes to use the new computing capabilities to discover new biomarkers and therapeutic targets for childhood cancers.
The study aims to recruit 40 people in the United Kingdom to wear watch-sized sensors on their belts. By placing the sensors around the body's center of mass the team from Imperial College London hope to gather data on each individual's position and walking speed.
Mayo Clinic and IBM have teamed up to apply cutting-edge technology to the age-old problem of enrolling patients into clinical trials. Starting next year Mayo Clinic will use IBM's supercomputer Watson to automatically match patients to clinical trials.
With the security of Apple's cloud storage system under scrutiny following reports linking it to the leak of private photographs, the company has barred apps that store health information from using the platform. The stipulation is one of several made by Apple as it tries to expand into healthcare without creating privacy problems or angering regulators.
The tech-driven reimagining of well-established clinical research and healthcare practices is continuing apace, with Propeller Health raising $14.5 million to develop its GPS-enabled inhaler. Users attach a small device to the end of their inhaler which tracks when and where a dose was administered.
The Harvard Medical School professor has long advocated for greater openness, with the sharing of his own data through the Personal Genome Project a standout example
Prenatal testing business Sequenom is the first company to buy the technology, which has applications in any setting in which genetic data needs mapping, sorting and deduplicating.
With pharma trade groups now committed to publishing the synopses of clinical study reports for some drugs, big-name consortium TransCelerate BioPharma has published a guide on how to redact documents.
While the outside world still has little idea what Google's biotech Calico is planning, AbbVie has seen enough to convince it to commit at least $250 million to the startup.
Takeda Pharmaceutical's United Kingdom subsidiary has begun working with C4X Discovery to improve its lead discovery and hit identification. The agreement is centered on C4XD's 3D drug technology, a nuclear magnetic resonance-based method of viewing the structure of a molecule.
IBM has opened up its Watson supercomputer to drug researchers through a new cloud-based service. And Big Pharma companies are already on board, with Johnson & Johnson and Sanofi among the early adopters of the technology.
With its big claims about how artificial intelligence can slash drug development timelines and a lead candidate based on a coenzyme best known as a dietary supplement, Berg is always likely to provoke skepticism. But the company is sticking to its guns, with President and CTO Niven Narain pointing to early drug discovery successes as evidence of its legitimacy.
The theft of data on up to 4.5 million patients from Community Health Systems last month has intensified awareness of the porousness of hospital and life science digital security measures. And the postevent analysis has reconfirmed that pharma is a top target for hackers, and some companies are ill equipped to defend themselves.
With reports suggesting Apple is set to get deeper into health data tracking by introducing its own wearable device, the tech giant has tightened up its app privacy rules. The changes ban the sale of health data to advertisers, while maintaining app developers' right to share data from consenting users with third parties for medical research purposes.
Amazon is the latest tech giant to consider expanding into healthcare, but details of the online retailer's plans are sketchy.
Jazz Pharmaceuticals and Boston Scientific have begun using Box as their main platform for managing and collaborating on content.
Illumina has laid the groundwork for increased use of next-generation sequencing in clinical research by striking a deal with Big Pharma, which could result in the company disrupting diagnostics using its dominance in NGS.
Having committed to a fast rollout of APIs at the start of the summer, the FDA made good on its promise this week by making data on drug labeling available. And the regulator went beyond its initial commitment by releasing an API for medical device adverse events.
The first batch of Y Combinator-backed life science companies made their pitches at the incubator's Demo Day this week. And with one of the startups already bagging $4.5 million from angel investors, Y Combinator is optimistic it can continue to expand into healthcare.